|
Dear
DR. {{ $doctorName }},
Subject: Renal Function
Parameters in Indian patients with Type 2 Diabetes Mellitus on
oral
antidiabetic agents (REDORA-II)
The kidney
is arguably the most important target of microvascular damage in
diabetes. A
substantial proportion of individuals with diabetes will develop
kidney disease owing to
their disease and/or other co-morbidity, including hypertension and
ageing-related
nephron loss. Thus, preventing and managing CKD in patients with
diabetes is now a key
aim of overall management of diabetes
Guidelines recommend that diabetic patients should
undergo annual testing for kidney
function using serum creatinine-based eGFR and urine tests for
abnormal levels of
albumin excretion to evaluate presence of any dysfunction. The
history of glycemic and
blood pressure control should also be considered as factors
predisposing to diabetic
kidney disease in patients with longstanding diabetes
Age, duration of diabetes, ethnicity, and family history
diabetes, hypertension & kidney
disease are some of the non-modifiable risk factors, while obesity,
uncontrolled diabetes,
dyslipidemia, and hypertension are some of modifiable risk factors
that have been
identified.
KDOQI guidelines recommends all patients
with type 2 diabetes should have their renal
function screened at least annually post diagnosis, using both ACR
and eGFR. More
frequent monitoring is appropriate for individuals with established
renal impairment and
those at increased risk of progressive kidney disease
Several glucose-lowering agents are purported to have pleiotropic
Reno protective actions
in patients with diabetes and CKD beyond glucose lowering These
drugs include
metformin, dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon-like
peptide 1 (GLP1)
analogues, thiazolidinediones and sodium/glucose co-transporter 2
(SGLT2) inhibitors
The present study is planned to evaluate effect of
duration of diabetes and associated risk
factors on renal function, and also understand utilization pattern
of antidiabetic drugs in
T2DM with CKD.
We invite you to participate in this study. On acceptance, you will
need to capture the
relevant data as mentioned in the standard Data Collection Form
(DCF) provided, from
the patient’s medical records (case papers and investigational
reports – hereafter referred
as source documents).
We would recommend you to capture data fulfilling the
criteria as outlined in the protocol
and whose relevant laboratory investigations are available for the
preceding 3 months.
We wish to inform you that the DCF will capture all data in
de-identified form and any
identifiable parameters which may potentially disclose the identity
of the patient such as
name or address will strictly not be captured so as to ensure we
maintain patient
confidentiality. We would encourage you to carefully fill all
available information to the
fullest as recommended in the DCF.
|
}}){kind=logo}